Compare · BTI vs ONCR
BTI vs ONCR
Side-by-side comparison of British American Tobacco Industries p.l.c. (BTI) and Oncorus Inc. (ONCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTI and ONCR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- BTI is the larger of the two at $130.80B, about 1588.7x ONCR ($82.3M).
- BTI has hit the wire 9 times in the past 4 weeks while ONCR has been quiet.
- BTI has more recent analyst coverage (14 ratings vs 0 for ONCR).
- Company
- British American Tobacco Industries p.l.c.
- Oncorus Inc.
- Price
- $59.94+0.40%
- $0.12-10.15%
- Market cap
- $130.80B
- $82.3M
- 1M return
- +2.80%
- -
- 1Y return
- +26.22%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- 2020
- News (4w)
- 9
- 0
- Recent ratings
- 14
- 0
British American Tobacco Industries p.l.c.
British American Tobacco p.l.c. provides tobacco and nicotine products to consumers worldwide. It offers vapour products, tobacco heating products, and modern oral products; combustible products; and traditional oral products, such as Swedish-style snus and American moist snuff. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.
Oncorus Inc.
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest BTI
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- Large owner Bt De Investments Inc. converted options into 95,281,277 shares and was granted 14,662,765 shares (SEC Form 4)
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
Latest ONCR
- SEC Form DEFA14A filed by Oncorus Inc.
- SEC Form 15-12G filed by Oncorus Inc.
- SEC Form DEFA14A filed by Oncorus Inc.
- Oncorus Inc. filed SEC Form 8-K: Leadership Update, Other Events, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form RW filed by Oncorus Inc.
- Oncorus Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update